Quarterly report pursuant to Section 13 or 15(d)

Licenses Acquired

v3.10.0.1
Licenses Acquired
6 Months Ended
Jun. 30, 2018
Licenses Acquired [Abstract]  
Licenses Acquired
8.
Licenses Acquired
 
In accordance with ASC 730-10-25-1, Research and Development, costs incurred in obtaining technology licenses are charged to research and development expense if the technology licensed has not reached technological feasibility and has no alternative future use. The licenses purchased by the Company and its’ subsidiaries require substantial completion of research and development, regulatory and marketing approval efforts in order to reach technological feasibility. As such, for the three and six months ended June 30, 2018 and 2017, the purchase price of licenses acquired was classified as research and development-licenses acquired in the Condensed Consolidated Statements of Operations, as reflected in the table below:
 
 
 
For the Three Months Ended June 30,
 
For the Six Months Ended June 30,
 
($ in thousands)
 
2018
 
2017
 
2018
 
2017
 
Fortress
 
$
–
 
$
300
 
$
–
 
$
300
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fortress Companies:
 
 
 
 
 
 
 
 
 
 
 
 
 
Checkpoint
 
 
–
 
 
–
 
 
–
 
 
400
 
Helocyte
 
 
–
 
 
–
 
 
21
 
 
–
 
Mustang
 
 
–
 
 
1,500
 
 
75
 
 
2,075
 
Cellvation
 
 
–
 
 
–
 
 
1
 
 
–
 
Caelum
 
 
–
 
 
–
 
 
–
 
 
219
 
Cyprium
 
 
–
 
 
–
 
 
–
 
 
100
 
Aevitas
 
 
1
 
 
–
 
 
1
 
 
–
 
Total
 
$
1
 
$
1,800
 
$
98
 
$
3,094
 
 
Checkpoint
 
The table below provides a summary of Checkpoint’s expense related to its licenses, for the three and six months ended June 30, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:
 
 
 
For the Three Months Ended June 30,
 
For the Six Months Ended June 30,
 
($ in thousands)
 
2018
 
2017
 
2018
 
2017
 
Jubliant Biosys License CK-103
 
$
–
 
$
–
 
$
–
 
$
400
 
Total Licenses Acquired Expense
 
$
–
 
$
–
 
$
–
 
$
400
 
 
See Note 21 for revenue recognized in connection with the Jubilant license under a sublicense agreement with TGTX, a related party.
 
Mustang
 
The table below provides a summary of Mustang’s expense related to its licenses, for the three and six months ended June 30, 2018 and 2017 by license as recorded in the Condensed Consolidated Statements of Operations:
 
 
 
For the Three Months Ended June 30,
 
For the Six Months Ended June 30,
 
($ in thousands)
 
2018
 
2017
 
2018
 
2017
 
City of Hope (COH) IL-13 License
 
$
–
 
$
–
 
$
–
 
$
250
 
COH IV/ICV License
 
 
–
 
 
–
 
 
–
 
 
125
 
COH HER2 License
 
 
–
 
 
600
 
 
–
 
 
600
 
COH CS-1 License
 
 
–
 
 
600
 
 
–
 
 
600
 
COH License for PSCA
 
 
–
 
 
300
 
 
–
 
 
500
 
Manufacturing License
 
 
–
 
 
–
 
 
75
 
 
–
 
Total licenses acquired expense
 
$
–
 
$
1,500
 
$
75
 
$
2,075
 
 
Caelum
 
For the three and six months ended June 30, 2018 and 2017, respectively, Caelum recorded expense of approximately $0 and $0, and $0 and $0.2 million in connection with its license for CAEL-101 from Columbia University.
 
Cyprium
 
For the three and six months ended June 30, 2018 and 2017, respectively, Cyprium recorded expense of approximately $0 and $0, and $0 and $0.1 million in connection with its license for CUTX-101 (copper histidinate injection) from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (“NICHD”).